Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$429.77M$429.77M+38.9% vs Q3 2023 Net Income$33.61M$33.61MN/M vs Q3 2023 EPS Diluted$0.34$0.34N/M vs Q3 2023 Gross Profit$338,080,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Operating Cash Flowderived-$70,699,000N/M Free Cash Flowderived-$107,962,000N/M Margins · derivedGross margin78.7%
Operating margin5.2%+11.9 pt vs Q3 2023
Net margin7.8%+21.1 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 6, 2024 · 37 d after period end